Subscribe to RSS
DOI: 10.1055/s-0039-1677796
Low-Molecular-Weight Heparin in Cancer Patients: Overview and Indications
Publication History
13 September 2018
03 January 2019
Publication Date:
31 January 2019 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00034925/201901/lookinside/thumbnails/10-1055-s-0039-1677796_180054-1.jpg)
Abstract
Although venous thromboembolism (VTE) is a well-known cause of death in patients with cancer, both its treatment and prevention remain a challenge in daily practice. Direct oral anticoagulants have emerged as safe and efficacious alternatives to vitamin K antagonists in the general population, and recent clinical trials also support their use in select patients with cancer-associated VTE. Despite this, low-molecular-weight heparins (LMWHs), a comparatively ancient class of antithrombotic drugs, remain the anticoagulants of choice in many indications relevant to modern haematology and oncology. In addition to the treatment of established VTE, these indications include VTE prophylaxis in surgical or acutely ill, hospitalized medical cancer patients as well as the prevention of VTE in high-risk patients undergoing ambulatory chemotherapy. In a constantly changing landscape of approved anticancer agents, this review article summarizes pivotal clinical trial data and guideline recommendations regarding the use of LMWH in haematological and oncological patients, who constitute a highly vulnerable patient population due to their increased risk for both bleeding and VTE recurrence.
Zusammenfassung
Obwohl die venöse Thromboembolie (VTE) bekanntermaßen zur Mortalität von Krebspatienten beiträgt, stellen ihre Therapie und Prophylaxe unverändert eine große Herausforderung dar. Direkte orale Antikoagulantien (DOAKs) haben sich bei nichtonkologischen Patienten als sichere und wirksame Alternativen zu den Vitamin K-Antagonisten etabliert. Zudem legen kürzlich publizierte Studien den Einsatz von DOAKs bei ausgewählten Krebspatienten mit VTE nahe. Nichtsdestotrotz bleiben niedermolekulare Heparine (NMHs), eine vergleichsweise alte Substanzklasse, die Antikoagulantien der Wahl in einer Reihe von Indikationen, die auch in der modernen Hämatologie und Onkologie von hoher Relevanz sind. Hierzu zählt neben der VTE-Therapie die VTE-Prophylaxe bei chirurgischen oder akut kranken, hospitalisierten internistischen sowie bei ambulanten Tumorpatienten mit hohem VTE-Risiko. In einer sich ständig wandelnden Landschaft von zugelassenen Krebstherapeutika fasst diese Übersichtsarbeit wichtige Studiendaten und Leitlinienempfehlungen bezüglich des Einsatzes von NMH bei Tumorpatienten zusammen, die aufgrund ihres hohen Blutungs- und VTE-Rezidivrisikos ein besonders vulnerables Kollektiv darstellen.
-
References
- 1 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
- 2 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
- 3 Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 2017; 117 (01) 57-65
- 4 Prandoni P, Lensing AW, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
- 5 Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18 (17) 3078-3083
- 6 Marmé D. Advances in cancer therapy: targeted therapies. Oncol Res Treat 2016; 39 (12) 758-759
- 7 Wang M, Yin B, Wang HY, Wang RF. Current advances in T-cell-based cancer immunotherapy. Immunotherapy 2014; 6 (12) 1265-1278
- 8 Benson III AB. Colon cancer: the new chronic disease. J Natl Compr Canc Netw 2014; 12 (11) 1497-1499
- 9 Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 2016; 34 (24) 2851-2857
- 10 Gedye C, van der Westhuizen A, John T. Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities. Intern Med J 2015; 45 (07) 696-701
- 11 Titov A, Petukhov A, Staliarova A. , et al. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. Cell Death Dis 2018; 9 (09) 897
- 12 Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 2013; 36 (06) 413-426
- 13 Levitan N, Dowlati A, Remick SC. , et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78 (05) 285-291
- 14 Lyman GH, Khorana AA, Kuderer NM. , et al; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31 (17) 2189-2204
- 15 Farge D, Bounameaux H, Brenner B. , et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2016; 17 (10) e452-e466
- 16 Streiff MB. ; National Comprehensive Cancer Center Network. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res 2010; 125 (Suppl. 02) S128-S133
- 17 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
- 18 Monreal M, Falgá C, Valdés M. , et al; Riete Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 4 (09) 1950-1956
- 19 Voigtlaender M, Langer F. Management of cancer-associated venous thromboembolism - a case-based practical approach. Vasa 2018; 47 (02) 77-89
- 20 Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood 2013; 122 (14) 2310-2317
- 21 Lim HY, Nandurkar H, Ho P. Direct oral anticoagulants and the paradigm shift in the management of venous thromboembolism. Semin Thromb Hemost 2018; 44 (03) 261-266
- 22 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
- 23 Voigtlaender M, Langer F. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?. Hamostaseologie 2017; 37 (04) 241-255
- 24 Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e24S-e43S
- 25 Lee AY, Levine MN, Baker RI. , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
- 26 Lee AYY, Kamphuisen PW, Meyer G. , et al; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 (07) 677-686
- 27 Lee AY, Rickles FR, Julian JA. , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23 (10) 2123-2129
- 28 Kamphuisen PW, Lee AYY, Meyer G. , et al; CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. J Thromb Haemost 2018; 16 (06) 1069-1077
- 29 Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. ; ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12 (04) 389-396
- 30 Meyer G, Marjanovic Z, Valcke J. , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162 (15) 1729-1735
- 31 Hull RD, Pineo GF, Brant RF. , et al; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119 (12) 1062-1072
- 32 Romera A, Cairols MA, Vila-Coll R. , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009; 37 (03) 349-356
- 33 Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015; 136 (03) 582-589
- 34 Francis CW, Kessler CM, Goldhaber SZ. , et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study. J Thromb Haemost 2015; 13 (06) 1028-1035
- 35 Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T. , et al. Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res 2017; 157: 90-96
- 36 Raskob GE, van Es N, Verhamme P. , et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
- 37 Kraaijpoel N, Di Nisio M, Mulder FI. , et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study. Thromb Haemost 2018; 118 (08) 1439-1449
- 38 Young AM, Marshall A, Thirlwall J. , et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
- 39 Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost 2011; 9 (Suppl. 01) 316-324
- 40 Geerts WH, Bergqvist D, Pineo GF. , et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl): 381S-453S
- 41 Akl EA, Kahale L, Sperati F. , et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database Syst Rev 2014; (06) CD009447
- 42 Warkentin TE, Levine MN, Hirsh J. , et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332 (20) 1330-1335
- 43 Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P. ; CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010; 8 (06) 1223-1229
- 44 Vedovati MC, Becattini C, Rondelli F. , et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg 2014; 259 (04) 665-669
- 45 Khorana AA, Weitz JI. Treatment challenges in venous thromboembolism: an appraisal of rivaroxaban studies. Thromb Haemost 2018; 118 (S 01): S23-S33
- 46 Kahn SR, Lim W, Dunn AS. , et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e195S-e226S
- 47 Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med 2014; 127 (01) 82.e1-86.e1
- 48 Haas S, Schellong SM, Tebbe U. , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. BMC Cancer 2011; 11: 316
- 49 Cohen AT, Spiro TE, Büller HR. , et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368 (06) 513-523
- 50 Goldhaber SZ, Leizorovicz A, Kakkar AK. , et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365 (23) 2167-2177
- 51 Spyropoulos AC, Ageno W, Albers GW. , et al; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018; 379 (12) 1118-1127
- 52 Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A. Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis. Acta Oncol 2014; 53 (09) 1230-1237
- 53 Agnelli G, Gussoni G, Bianchini C. , et al; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10 (10) 943-949
- 54 Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 2012; 7 (03) 291-292
- 55 Agnelli G, George DJ, Kakkar AK. , et al; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366 (07) 601-609
- 56 Khorana AA, Francis CW, Kuderer NM. , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Thromb Res 2017; 151: 89-95
- 57 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
- 58 Ay C, Dunkler D, Marosi C. , et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116 (24) 5377-5382
- 59 Pelzer U, Sinn M, Stieler J, Riess H. Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy? [in German]. Dtsch Med Wochenschr 2013; 138 (41) 2084-2088
- 60 Pabinger I, van Es N, Heinze G. , et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 2018; 5 (07) e289-e298
- 61 Pelzer U, Opitz B, Deutschinoff G. , et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol 2015; 33 (18) 2028-2034
- 62 Maraveyas A, Waters J, Roy R. , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012; 48 (09) 1283-1292
- 63 Haas SK, Freund M, Heigener D. , et al; TOPIC Investigators. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 2012; 18 (02) 159-165
- 64 Perry JR, Julian JA, Laperriere NJ. , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8 (09) 1959-1965
- 65 Phan M, John S, Casanegra AI. , et al. Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. J Thromb Thrombolysis 2014; 38 (02) 241-249
- 66 Terpos E, Kleber M, Engelhardt M. , et al; European Myeloma Network. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 2015; 100 (10) 1254-1266
- 67 Akl EA, Vasireddi SR, Gunukula S. , et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011; (06) CD006649
- 68 Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost 2007; 33 (07) 688-694
- 69 Borsig L. Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb Res 2010; 125 (Suppl. 02) S66-S71
- 70 Amirkhosravi A, Meyer T, Amaya M. , et al. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 2007; 33 (07) 643-652
- 71 Langer F, Bokemeyer C. Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor. Hamostaseologie 2012; 32 (02) 95-104
- 72 Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004; 92 (03) 627-633
- 73 Sudha T, Yalcin M, Lin HY. , et al. Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. Cancer Lett 2014; 350 (1–2): 25-33
- 74 Maraveyas A, Johnson MJ, Xiao YP, Noble S. Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins. Cancer Metastasis Rev 2010; 29 (04) 777-784
- 75 Nadir Y, Brenner B. Heparanase coagulation and cancer progression. Best Pract Res Clin Haematol 2009; 22 (01) 85-92
- 76 Kakkar AK, Levine MN, Kadziola Z. , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22 (10) 1944-1948
- 77 Klerk CP, Smorenburg SM, Otten HM. , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23 (10) 2130-2135
- 78 van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011; 29 (15) 2071-2076
- 79 Macbeth F, Noble S, Evans J. , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. J Clin Oncol 2016; 34 (05) 488-494
- 80 Ek L, Gezelius E, Bergman B. , et al; Swedish Lung Cancer Study Group (SLUSG). Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial. Ann Oncol 2018; 29 (02) 398-404
- 81 Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 81-91
- 82 Carrier M, Lazo-Langner A, Shivakumar S. , et al. Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations. Curr Oncol 2015; 22 (01) 49-59
- 83 Samuelson Bannow BT, Lee A, Khorana AA. , et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16 (06) 1246-1249